CAS · 9007-72-1
Product Overview
Ferinject is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance: | Brown powder |
|---|---|
| Assay (Iron): | 24.0%~33.0% (on dried basis) |
| Maltodextrin (Calculated on dextrose): | 25.0%~50.0% (on dried basis) |
| Iron salt Identification: | Should be positive reaction |
| Maltodextrin identification: | Thin-layer chromatography: The principal spot in the chromatogram obtained with test solution should be similar in position, colour, and size to those with reference solution a |
| Solubility: | Freely soluble in water, practically insoluble in methanol, ethanol, and methylene chloride |
| Osmolarity: | 230 mOsmol/kg~360 mOsmol/kg |
| Acidity: | 5.0~7.0 |
| Molecular weight and Distribution: | Mw: 130 kDa~230 kDa; Mn: 90 kDa min; Mw/Mn: 1.5 max |
| Sodium Chloride content: | 6.0% max |
| Limit of Iron [Fe(II)]: | 1.2% max |
| Ethanol: | 0.5% max |
| Lead (Pb): | 1.2 ppm max |
| Cadmium (Cd): | 0.48 ppm max |
| Arsenic (As): | 3.6 ppm max |
| Nickel (Ni): | 4.8 ppm max |
| Cobalt (Co): | 1.2 ppm max |
| Vanadium (V): | 2.4 ppm max |
| Bacterial endotoxins: | 0.2 EU/mg Fe max |
| Aerobic bacteria: | 100 cfu/g max |
| Yeast and mold: | 10 cfu/g max |
| Loss on drying: | 10.0% max |
| Iron/Maltodextrin: | 0.5~0.8 |
Applications
Ferinject, also known as ferric carboxymaltose, is an intravenous iron complex widely used in the medical and pharmaceutical fields for the treatment of iron deficiency and iron deficiency anemia (IDA). It is primarily administered to patients who cannot tolerate or do not respond adequately to oral iron supplements, including those with chronic kidney disease, inflammatory bowel disease, postpartum anemia, or heart failure. In clinical settings, Ferinject provides a rapid and effective method for replenishing iron stores and restoring hemoglobin levels. Its controlled release properties allow for high-dose administration in a single infusion, reducing the frequency of treatments. Additionally, Ferinject is used in research for developing improved iron delivery systems and evaluating iron metabolism and absorption in various physiological and pathological conditions.
Benefits
The benefits of Ferinject derive from its high bioavailability, safety profile, and controlled iron release characteristics. The ferric carboxymaltose complex provides a stable structure that minimizes the release of free iron, thereby reducing oxidative stress and gastrointestinal side effects often associated with other iron formulations. Its ability to deliver large doses in a single infusion ensures rapid correction of anemia while enhancing patient compliance and treatment convenience. Ferinject is well-tolerated, with low incidence of hypersensitivity or adverse reactions, and does not require test dosing before administration. Its pharmacokinetic properties enable predictable and sustained iron delivery, supporting long-term maintenance of iron stores. Furthermore, it offers clinicians flexibility in dosing and timing, making it suitable for both hospital and outpatient settings.
Conclusion
Ferinject (CAS 9007-72-1) is an advanced intravenous iron formulation designed for efficient and well-tolerated treatment of iron deficiency and anemia. Its stable ferric carboxymaltose complex allows safe, high-dose administration with rapid and sustained therapeutic outcomes. By combining efficacy, safety, and patient convenience, Ferinject represents a significant advancement in iron replacement therapy and continues to play an essential role in modern clinical practice.
Previous
Next